Deals

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031
NASDAQ: REGNRegeneron Pharmaceuticals

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response…

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BaiduRundo Med-Tech

Rundo Med-Tech Partners with Baidu to Advance Digital Clinical Trials

BiotechChina Medical System

China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea

Betta PharmaceuticalsFinance

Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang

Auto-immuneBiotech

WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development

Show More